ProfileGDS5678 / 1417691_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 90% 89% 89% 92% 89% 89% 90% 91% 90% 90% 89% 90% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.979689
GSM967853U87-EV human glioblastoma xenograft - Control 27.3123890
GSM967854U87-EV human glioblastoma xenograft - Control 37.133689
GSM967855U87-EV human glioblastoma xenograft - Control 47.2779289
GSM967856U87-EV human glioblastoma xenograft - Control 57.7564692
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.802989
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.8535489
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.2291590
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.397691
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2473190
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1821790
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1335189
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.1652690
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.2436390